People, Product and Company News from the 3/18 News Brief
The FDA approved Sepracor’s Xopenex (levalbuterol tartrate) inhalation aerosol, for the treatment or prevention of bronchospasm in adults, adolescents ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.